MedTrace Logo

Botulinum Toxin Therapy in Hidradenitis Suppurativa

NCT05403710 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-09-15

No results posted yet for this study

Summary

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Conditions

Interventions

DRUG

Botulinum toxin

Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin

Sponsors & Collaborators

  • Hidradenitis Suppurativa Foundation

    collaborator UNKNOWN

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • University of Massachusetts, Worcester

    lead OTHER

Principal Investigators

  • Sarah K Whitley, MD PhD · Assistant Professor of Dermatology

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-07
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05403710 on ClinicalTrials.gov